Statements (67)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:small_interfering_RNA |
| gptkbp:approvalYear |
2020
|
| gptkbp:approvedBy |
gptkb:European_Medicines_Agency
gptkb:U.S._Food_and_Drug_Administration |
| gptkbp:ATCCode |
C10AX16
|
| gptkbp:brand |
gptkb:Leqvio
|
| gptkbp:CASNumber |
1639324-58-2
|
| gptkbp:chemicalFormula |
C529H642F10N176O316P43S6
|
| gptkbp:developer |
gptkb:Alnylam_Pharmaceuticals
gptkb:Novartis |
| gptkbp:eliminationHalfLife |
9-13 days
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
PCSK9 inhibitor
|
| gptkbp:pregnancyCategory |
Not assigned (US)
|
| gptkbp:reduces |
gptkb:LDL_cholesterol
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
bronchitis
nausea diarrhea dizziness fatigue headache hypertension urinary tract infection back pain cough injection site reaction rash elevated liver enzymes injection site pain hypersensitivity dyspnea arthralgia myalgia nasopharyngitis pain in extremity musculoskeletal pain increased creatine kinase injection site abscess injection site atrophy injection site bruising injection site cellulitis injection site discomfort injection site erythema injection site hematoma injection site hyperpigmentation injection site hypopigmentation injection site induration injection site infection injection site mass injection site necrosis injection site nodule injection site pruritus injection site rash injection site scab injection site scar injection site swelling injection site ulcer injection site warmth |
| gptkbp:target |
gptkb:PCSK9_mRNA
|
| gptkbp:UNII |
6Z1Y2V4S2E
|
| gptkbp:usedFor |
gptkb:familial_hypercholesterolemia
atherosclerotic cardiovascular disease |
| gptkbp:bfsParent |
gptkb:The_Medicines_Company
|
| gptkbp:bfsLayer |
6
|
| https://www.w3.org/2000/01/rdf-schema#label |
Inclisiran
|